这是美国癌症协会根据国家癌症研究所和疾病控制与预防中心的高质量发病率和死亡率数据每两年更新一次的女性乳腺癌统计数据。乳腺癌发病率继续呈上升趋势，2012-2021年间每年上升1%，主要局限于局限性阶段和激素受体阳性疾病。与 50 岁及以上女性（每年 0.7%）相比，50 岁以下女性（每年 1.4%）的增幅更大，这一现象仅在白人女性中显着。亚裔美国人/太平洋岛民女性在两个年龄组中增长最快（分别为每年 2.7% 和 2.5%）；因此，年轻的亚裔美国人/太平洋岛民女性在 2000 年的发病率第二低（每 10 万人 57.4 人），但在 2021 年发病率最高（每 10 万人 86.3 人），与白人女性（每 10 万人 86.4 人）并列，超过黑人女性（每 10 万人 81.5 人）。相比之下，1989 年至 2022 年期间，总体乳腺癌死亡率持续下降 44%，意味着在此期间乳腺癌死亡人数减少了 517,900 人。然而，并非所有女性都经历了这一进步。自 1990 年以来，美洲印第安人/阿拉斯加原住民妇女的死亡率保持不变，黑人妇女的死亡率比白人妇女高 38%，尽管黑人妇女的死亡率比白人妇女低 5%。尽管黑人与白人之间的差异在一定程度上反映了更多的三阴性癌症，但除局部疾病外，黑人女性在每种乳腺癌亚型和分期中的生存率都是最低的，她们被诊断出局部疾病的可能性比白人女性低 10%（58% vs. 10%）。 68%），强调了健康社会决定因素的缺点。通过改善临床试验代表性和获得高质量筛查和治疗的机会，减少种族、民族和社会差异，可以加速对抗乳腺癌的进展。© 2024 作者。 CA：Wiley periodicals LLC 代表美国癌症协会出版的《临床医生癌症杂志》。

This is the American Cancer Society's biennial update of statistics on breast cancer among women based on high-quality incidence and mortality data from the National Cancer Institute and the Centers for Disease Control and Prevention. Breast cancer incidence continued an upward trend, rising by 1% annually during 2012-2021, largely confined to localized-stage and hormone receptor-positive disease. A steeper increase in women younger than 50 years (1.4% annually) versus 50 years and older (0.7%) overall was only significant among White women. Asian American/Pacific Islander women had the fastest increase in both age groups (2.7% and 2.5% per year, respectively); consequently, young Asian American/Pacific Islander women had the second lowest rate in 2000 (57.4 per 100,000) but the highest rate in 2021 (86.3 per 100,000) alongside White women (86.4 per 100,000), surpassing Black women (81.5 per 100,000). In contrast, the overall breast cancer death rate continuously declined during 1989-2022 by 44% overall, translating to 517,900 fewer breast cancer deaths during this time. However, not all women have experienced this progress; mortality remained unchanged since 1990 in American Indian/Alaska Native women, and Black women have 38% higher mortality than White women despite 5% lower incidence. Although the Black-White disparity partly reflects more triple-negative cancers, Black women have the lowest survival for every breast cancer subtype and stage except localized disease, with which they are 10% less likely to be diagnosed than White women (58% vs. 68%), highlighting disadvantages in social determinants of health. Progress against breast cancer could be accelerated by mitigating racial, ethnic, and social disparities through improved clinical trial representation and access to high-quality screening and treatment.© 2024 The Author(s). CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.